MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) is a publicly traded Healthcare sector company. As of September 22, 2026, MLTX trades at $13.38 with a market cap of $1.05B and a P/E ratio of -3.77. MLTX moved +5.42% today. Year to date, MLTX is -4.78%; over the trailing twelve months it is -76.66%. Its 52-week range spans $5.95 to $62.75. Analyst consensus is strong buy with an average price target of $38.00. Rallies surfaces MLTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks MLTX insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $13.38 |
| Market Cap | $1.05B |
| P/E Ratio | -3.77 |
| EPS | $-3.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.75 |
| 52-Week Low | $5.95 |
| Volume | 1.79M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-230.32M |
| Gross Margin | 0.00% |
9 analysts cover MLTX: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.00.